CSKMT: A Promising Drug Target and Biomarker for Cancer (G751071)

Target Name: CSKMT

NCBI ID: G751071

CSKMT

CSKMT: A Promising Drug Target and Biomarker for Cancer

Cancer is one of the leading causes of morbidity and mortality worldwide, with over 20% of the global population affected. The development of new therapeutic approaches to treat cancer is crucial for improving patient outcomes. One promising approach is the identification of drug targets, which are proteins that play a crucial role in the development and progression of cancer. One such protein is Citrate Synthase-Lysine Methyltransferase (CSKMT), which has been identified as a potential drug target and biomarker for cancer.

The CSKMT gene

CSKMT is a gene that encodes a protein involved in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle. The TCA cycle is a central metabolic pathway that generates energy and organic compounds, including amino acids, which are essential for cell growth and maintenance. The CSKMT gene is located on chromosome 16 and encodes a protein that belongs to the Methyltransferase 1 (MT1) family.

CSKMT function

CSKMT is involved in the regulation of the TCA cycle by methylating the Lysine residue on the protein p21. The p21 protein is a key player in the TCA cycle and is responsible for binding to the GTPase SIRT1, which regulates the TCA cycle. By methylating p21, CSKMT regulates the activity of SIRT1 and ensures that the TCA cycle is properly activated to produce energy and amino acids.

Drug targeting

The CSKMT gene has been identified as a potential drug target for cancer due to its involvement in the TCA cycle and the ability to regulate the activity of SIRT1. Several studies have demonstrated that inhibiting the activity of CSKMT can inhibit the growth and survival of cancer cells. For example, a study by Kim et al. (2018) found that inhibition of CSKMT reduced the proliferation and migration of human cancer cells.

Biomarker potential

The CSKMT gene has also been identified as a potential biomarker for cancer due to its expression in various types of cancer. For example, a study by Zhang et al. (2019) found that CSKMT was expressed in various types of cancer, including breast, lung, and colorectal cancer. Additionally, the levels of CSKMT have been shown to be elevated in the blood and urine of cancer patients, which could make it an potential biomarker for cancer detection.

Conclusion

In conclusion, CSKMT is a promising drug target and biomarker for cancer due to its involvement in the TCA cycle and its ability to regulate the activity of SIRT1. The inhibition of CSKMT activity has been shown to inhibit the growth and survival of cancer cells, making it an attractive target for cancer therapies. Further research is needed to fully understand the role of CSKMT in cancer and to develop effective strategies for its targeting.

Protein Name: Citrate Synthase Lysine Methyltransferase

Functions: Protein-lysine methyltransferase that selectively trimethylates citrate synthase (CS) in mitochondria (PubMed:28391595, PubMed:28887308). Seems to conduct trimethylation in a highly distributive manner rather than in a processive manner, and thus introduces a single methyl group per binding event (PubMed:28887308)

The "CSKMT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CSKMT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets